These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22881442)

  • 1. Rational design of a dry powder inhaler: device design and optimisation.
    Friebel C; Steckel H; Müller BW
    J Pharm Pharmacol; 2012 Sep; 64(9):1303-15. PubMed ID: 22881442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.
    de Boer AH; Hagedoorn P; Westerman EM; Le Brun PP; Heijerman HG; Frijlink HW
    Eur J Pharm Sci; 2006 Jun; 28(3):171-8. PubMed ID: 16650739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
    Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
    Fyrnys B; Stang N; Wolf-Heuss E
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental investigation of design parameters on dry powder inhaler performance.
    Ngoc NT; Chang L; Jia X; Lau R
    Int J Pharm; 2013 Nov; 457(1):92-100. PubMed ID: 24055597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
    Grant AC; Walker R; Hamilton M; Garrill K
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an inhalation chamber and a dry powder inhaler device for administration of pulmonary medication in animal model.
    Sinha B; Mukherjee B
    Drug Dev Ind Pharm; 2012 Feb; 38(2):171-9. PubMed ID: 21721851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
    Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Genuair® inhaler: a novel, multidose dry powder inhaler.
    Chrystyn H; Niederlaender C
    Int J Clin Pract; 2012 Mar; 66(3):309-17. PubMed ID: 22340451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained mechanical and clinical functionality of the flexhaler dry powder inhaler.
    Lööf T; Elfman P; Ström P; Törngren A; Borgström L
    J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):381-8. PubMed ID: 18823260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can patients use all dry powder inhalers equally well?
    Gustafsson P; Taylor A; Zanen P; Chrystyn H
    Int J Clin Pract Suppl; 2005 Dec; (149):13-8. PubMed ID: 16279998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. True adherence with the Turbuhaler in young children with asthma.
    Nikander K; Turpeinen M; Pelkonen AS; Bengtsson T; Selroos O; Haahtela T
    Arch Dis Child; 2011 Feb; 96(2):168-73. PubMed ID: 21097795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication Tracking: Design and Fabrication of a Dry Powder Inhaler with Integrated Acoustic Element by 3D Printing.
    Li Y; Bohr A; Jensen H; Rantanen J; Cornett C; Beck-Broichsitter M; Bøtker JP
    Pharm Res; 2020 Jan; 37(3):38. PubMed ID: 31965333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
    Cordts E; Steckel H
    Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.